Table 1. Baseline demographic and clinical characteristics (ITT population).
| Characteristic | Pioglitazone (n=69) | Glimepiride (n=66) | P value |
|---|---|---|---|
| Age, yr | 60.7±9.1 | 58.5±10.4 | 0.190 |
| Male sex | 34 (49.3) | 30 (45.5) | 0.657 |
| Body weight, kg | 64.0±10.0 | 65.8±10.3 | 0.295 |
| BMI, kg/m2 | 24.4±3.2 | 24.9±2.8 | 0.327 |
| Disease duration, yr | 10.6±8.2 | 9.7±6.7 | 0.478 |
| HbA1c, % | 8.25±0.58 | 8.16±0.61 | 0.386 |
| Fasting plasma glucose, mg/dL | 171.6±30.0 | 170.8±30.9 | 0.880 |
| SBP, mm Hg | 124±13 | 125±13 | 0.646 |
| DBP, mm Hg | 72±10 | 74±10 | 0.294 |
| Triglyceride, mg/dL | 68 (87–155) | 80 (96–176) | 0.237 |
| Total cholesterol, mg/dL | 156±33 | 151±33 | 0.310 |
| LDL-C, mg/dL | 90±32 | 87±27 | 0.549 |
| HDL-C, mg/dL | 51±14 | 47±10 | 0.136 |
| Hypertension | 36 (52.2) | 38 (37.6) | 0.528 |
| Dyslipidemia | 40 (58.0) | 41 (62.1) | 0.623 |
| Diabetic retinopathy | 12 (17.4) | 5 (7.6) | 0.086 |
| Diabetic neuropathy | 19 (27.5) | 16 (24.2) | 0.662 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
ITT, intention-to-treat; BMI, body mass index; HbA1c, glycosylated hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol.